ClinicalTrials.gg
CompletedNCT02005744Updated Jul 4, 2016

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

A Phase 1 interventional study of CKD-501 in Liver Dysfunction, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-04.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Liver Diseases with a site in Korea, Republic of — 9 open to participants now, 12 under way, 3 of them phase 3. Liver Diseases · Korea, Republic of.

Enrollment
23rd of 27
26 · median 92
Started
2014
with 3 others
Phase 1
6 of 35
1 open now
Registered
4th of 35
by date

Among the 35 studies in Liver Diseases with a site in Korea, Republic of, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2014, is one of 6 in phase 1, and was the 4th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 152 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

9 of the 35 studies in Liver Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Liver Diseases with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.

Read the detailed description

A Phase 1, Non-randomized, Open, Parallel-Group study.

03

Conditions studied

  • Liver Dysfunction

Browse trials for

Keywords

  • CKD-501
04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

A. Inclusion Criteria

[The subjects with impaired hepatic function]

  1. The subjects who are 19 to 64 years old
  2. The subjects with stable hepatic disease and impaired hepatic function as A or B
  3. Body Weight ≥ 55kg
  4. If females, Negative for pregnancy test at the screening and pre dose of Day 1
  5. The subjects who agreed with performing during the study
  6. The subjects who agreed with written

[The subjects with normal hepatic function]

  1. The subjects who are 19 to 64 years old
  2. The subjects who are matched impaired hepatic function by gender, age(± 5years) and body weight(± 10kg)
  3. If females, Negative for pregnancy test at the screening and pre dose of Day 1
  4. The subjects who agreed with performing contraception during the study
  5. The subjects who agreed with written informed consent

B. exclusion criteria

[The subjects with impaired hepatic function]

  1. The subjects with impaired hepatic function as Child-Pugh C
  2. The subjects had a portosystemic shunt surgery
  3. The subjects had a liver transplantation or unsuitable for the study by the investigator's judgement(for examples, hepatic encephalopathy grade 3 or 4, stroke, heart failure, cancer etc.) but The subject is eligible to participate if had not chemotherapy or radiofrequency ablation therapy within 6months)
  4. The subjects have a gastrointestinal disease or surgery which can be effected in absorption of product
  5. The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1
  6. Positive for anti- Ab or venereal disease research laboratory etc.

[The subjects with normal hepatic function]

  1. The subjects with liver disease or abnormal Laboratory test(Asparate transaminase >1.25 fold of upper normal limit, >1.25 fold of upper normal limit, Total >1.5 fold of upper normal limit)
  2. The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
  3. Estimated \< 60 mL/min/1.73m2 by Modification of Diet in Renal Disease formula
  4. Positive for , anti- virus Ab, anti-HIV Ab or venereal disease research laboratory
  5. The subjects with high blood pressure or low blood pressure(systolic blood pressure >150mmHg or \<100mmHg, diastolic blood pressure>90mmHg or \<60mmHg)
  6. The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1 etc.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Child Pugh A

    CKD-501 will be administered to patients who are included Child Pugh A

    Drug: CKD-501

  • Experimental
    Child Pugh B

    CKD-501 will be administered to patients who are included Child Pugh B

    Drug: CKD-501

  • Experimental
    Subject who are matched Child Pugh A

    CKD-501 will be administered to the Subjects who are matched Child Pugh A

    Drug: CKD-501

  • Experimental
    Subject who are matched Child Pugh B

    CKD-501 will be administered to the subjects who are matched Child Pugh B

    Drug: CKD-501

Interventions

  • CKD-501 0.5mg, PO(per oral), once

    Also known as: Lobeglitazone

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration(last) and Cmax of CKD-501

    Sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Time frame: 0 to 48 hours

Secondary outcomes

  1. Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite

    Sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Time frame: 0 to 48 hours

  2. Fraction Unbound of CKD-501 and its metabolite

    sampling timepoint(hours) : 1, 8

    Time frame: 1 and 8 hours

  3. Area Under the Concentration(last) and Cmax of the metabolite

    sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Time frame: o to 48 hours

  4. Metabolic ratio(metabolite/CKD-501)

    sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Time frame: 0 to 48 hours

Other outcomes

  1. Vital signs

    Time frame: up to 8 days

  2. Physical examination

    Time frame: up to 8 days

  3. Laboratory tests

    Time frame: up to 8 days

  4. Adverse events

    Time frame: up to 8 days

07

Study locations

1 site
  • Yonsei University Severance Hospital
    Soeul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Dec 9, 2013
Start
Mar 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Jul 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02005744
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Mar 2014
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Jul 4, 2016

Study contacts

Min Soo Park, Ph.D. M.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lobeglitazone

Start the discussion